Big Pharma has a huge appetite to identify and acquire novel treatments .
I remain convinced that Monepantel has intrinsic value which is calculated in the billions. The key question for PAA is how to realise maximum value in bringing our product to a commercial outcome.
Riluzole, the current standard of care for MND has $1bn+ annual sales. With a long patent runway and superior clinical results I expect Monepantel to figure highly on Big Pharma's radar.
Back in May we received the research paper from Prof Fairlie which looked at the anti-tumor activity of Monepantel across multiple human cancer types. It was heavy duty research many years in the making. The implications are mind-blowing.
For anyone who has not viewed the research paper:
https://onlinelibrary.wiley.com/doi/10.1002/cam4.6021
My feeling is that PAA will be targeting Phase 2 Human Cancer clinical trials as soon as finances permit. It has always been the ultimate objective. If a BP want to buy us out early, then I reckon the valuation of Monepantel as a combination therapy for multiple human cancers should be foremost in discussions.
PAA may be a minnow regarding our share price, but we have something of immense value. It may be a little while down the road, but I think we may be setting a new high benchmark in BioTech deals.
My opinion only, Cheers, Thrifty
- Forums
- ASX - By Stock
- FDA Application for Orphan Drug Designation , PAA, MPL
Big Pharma has a huge appetite to identify and acquire novel...
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.24M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.5¢ | $244.3K | 1.244M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 257206 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.195 |
15 | 925498 | 0.190 |
11 | 271447 | 0.185 |
17 | 418587 | 0.180 |
3 | 259030 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 257206 | 7 |
0.205 | 247264 | 3 |
0.210 | 193616 | 5 |
0.215 | 353018 | 4 |
0.220 | 479713 | 7 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online